NCT04388215

Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet

A Randomized, Double-blind, Multi-center, Therapeutic Confirmatory, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-828, D326, and D337 Combination Therapy in Hypertensive Patients With Dyslipidemia

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

to evaluate the efficacy and safety of CKD-828, D326, and D337 combination therapy in Hypertensive patients with Dyslipidemia

Detailed description

The purpose of this phase III study was to evaluate the efficacy and safety of CKD-348(CKD-828, D326, D337) tablet administration for treatment period(8 weeks) in essential hypertesive patients with Dyslipidemia.

Conditions

• Hypertension
• Dyslipidemias

Interventions

Type	Name	Description
DRUG	CKD-828	orally, 1 tablet once a day for 8 weeks
DRUG	CKD-828(placebo)	orally, 1 tablet once a day for 8 weeks
DRUG	D326	orally, 1 tablet once a day for 8 weeks
DRUG	D326(placebo)	orally, 1 tablet once a day for 8 weeks
DRUG	D337	orally, 1 tablet once a day for 8 weeks
DRUG	D337(placebo)	orally, 1 tablet once a day for 8 weeks
DRUG	D013	orally, 1 tablet once a day for 8 weeks
DRUG	D013(placebo)	orally, 1 tablet once a day for 8 weeks

Timeline

• Start date: 2019-10-23
• Primary completion: 2021-04-01
• Completion: 2021-04-01
• First posted: 2020-05-14
• Last updated: 2020-05-14

Locations

1 site across 1 country: South Korea